Human LILRB2/CD85d/ILT4 Alexa Fluor® 700-conjugated Antibody Summary
Accession # ACT64556
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of LILRB2/CD85d/ILT4 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) were stained with Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (Catalog # FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Alexa Fluor® 700-conjugated Monoclonal Antibody (Catalog # FAB2078N) or (B) Mouse IgG2AAlexa Fluor 700 Isotype Control (Catalog # IC003N). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1‑3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5‑9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by downregulation of costimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo (10‑12).
- Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7.
- Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317.
- Hunt, J.S. et al. (2005) FASEB J. 19:681.
- Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Colonna, M. et al. (1998) J. Immunol. 160:3096.
- Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
- Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
- Allen, R.L. et al. (2001) J. Immunol. 167:5543.
- Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
- Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
- Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human LILRB2/CD85d/ILT4 Alexa Fluor® 700-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human LILRB2/CD85d/ILT4 Alexa Fluor® 700-conjugated Antibody and earn rewards!
Have you used Human LILRB2/CD85d/ILT4 Alexa Fluor® 700-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image